Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-002059-40
    Sponsor's Protocol Code Number:ECT-LANS-IL2
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2012-09-03
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2012-002059-40
    A.3Full title of the trial
    Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patients
    Potenziamento degli effetti clinici e immunologici della chemioterapia neutralizzando il pH acido al sito tumorale: studio randomizzato di fase II in pazienti affetti da melanoma
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patients
    Potenziamento degli effetti clinici e immunologici della chemioterapia neutralizzando il pH acido al sito tumorale: studio randomizzato di fase II in pazienti affetti da melanoma
    A.3.2Name or abbreviated title of the trial where available
    ECT-LANS-IL2
    ECT-LANS-IL2
    A.4.1Sponsor's protocol code numberECT-LANS-IL2
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorISTITUTO NAZIONALE PER LA CURA TUMORI
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMinistero della Salute, Bandi Ricerca Finalizzata 2009
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
    B.5.2Functional name of contact pointCHIRURGIA GENERALE 4 CMS
    B.5.3 Address:
    B.5.3.1Street AddressVIA VENEZIAN 1
    B.5.3.2Town/ cityMILANO
    B.5.3.3Post code20133
    B.5.3.4CountryItaly
    B.5.4Telephone number0223902909
    B.5.5Fax number0223902404
    B.5.6E-mailannabella.diflorio@istitutotumori.mi.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Orodispersible tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLANSOPRAZOLE
    D.3.9.1CAS number 103577-45-3
    D.3.9.2Current sponsor codeLANS
    D.3.9.4EV Substance CodeSUB08403MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/g milligram(s)/gram
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeINIBITORE DI POMPA PROTONICA
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name BLEOMICINA NIPPON K.*1F 15MG
    D.2.1.1.2Name of the Marketing Authorisation holderAVENTIS PHARMA SpA
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBLEOMYCIN SULPHATE
    D.3.9.1CAS number 0011056-06-7
    D.3.9.4EV Substance CodeSUB11754MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeALTRI ANTIBIOTICI CITOTOSSICI/NEOPLASTICI
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name PROLEUKIN*EV 1F 18MUI
    D.2.1.1.2Name of the Marketing Authorisation holderNOVARTIS FARMA SpA
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntralesional use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNALDESLEUKIN
    D.3.9.1CAS number 110942-02-4
    D.3.9.2Current sponsor codeIL-2
    D.3.9.4EV Substance CodeSUB05303MIG
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number18000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic Cutaneous and Subcutaneous Melanoma
    Melanoma cutaneo metastatico
    E.1.1.1Medical condition in easily understood language
    STAGE IIIC-IVM1a Malignant Cutaneous melanoma
    Melanoma cutaneo maligno stadio IIIC-IVM1a
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 15.0
    E.1.2Level LLT
    E.1.2Classification code 10027481
    E.1.2Term Metastatic melanoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1. Significant increase in the systemic anti-tumor immune response (evaluated as IFN gamma Elispost in response to autologous melanoma cells or HLA-compatible antigenic peptides and phenotypic profile leukocyte, including of immunosoppressorie subpopulations immunosoppressorie as Treg and MDSC) in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment;
    2. Increase of pathological tumor response and of the anti-tumor immune infiltrate T, possibly associated with a decrease of negative regulatory cells (Treg and MDSC) in ECT treated lesions, in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment
    1. Aumento significativo della risposta immunitaria anti-tumorale sistemica (valutata come IFN gamma Elispost in risposta a cellule di melanoma autologhe o HLA-compatibili peptidi antigenici e profilo fenotipico leucocitario, inclusivo di sottopopolazioni immunosoppressorie quali Treg ed MDSC) nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo;
    2. Aumento della risposta tumorale patologica e dell’infiltrato immunitario T anti-tumorale, eventualmente associato ad una diminuzione di cellule regolatorie negative (Treg ed MDSC) nelle lesioni trattate con ECT, nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo
    E.2.2Secondary objectives of the trial
    1. Improvement of clinical response (assessed as % regression and TTR or TTP) in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment;
    2. Achievement of clinical response in untreated lesions, as a sign of systemic acquired effecacy in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment, assessed clinically or pathologically;
    3. Reduction of frequency and / or activity of negative regulation immune cells to, as MDSC and Treg in the peripheral blood of patients enrolled in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment
    1. Miglioramento della risposta clinica (valutata come % di regressione e TTR o TTP) nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo;
    2. Risposta clinica nelle lesioni non trattate, come segno di acquisita efficacia sistemica nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo, valutata clinicamente o patologicamente;
    3. Riduzione della frequenza e/o dell’attività di cellule immunitarie a regolazione negativa, come MDSC e Treg, nel sangue periferico dei pazienti arruolati nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients with metastatic melanoma IIIC / IV M1a meeting the following inclusion criteria will be eligible for the study.
    1. Age> 18
    2. Melanoma skin histo-and / or cytologically confirmed.
    3. Non- Ocular melanoma in advanced stage IIIC / IV M1 with the presence of multiple measurable cutaneous and/or subcutaneous lesions, suitable for biopsy, and for the application of electrodes;
    4. Number of lesions equal to or greater than six with a minimum size of the lesions of 0.5 cm.
    5. Performance status 0-2 (ECOG).
    6. Life expectancy  3 months.
    7. Locations of measurable and / or assessed metastases according to RECIST criteria confirmed by imaging. However, the evaluation of the lesions may be carried out using the clinical examination with digital photography and / or by ultrasound.
    8. A previous chemo-and/or immune/bio-chemotherapy and/or vaccination are allowed (however, a washout period of at least 4 weeks is required).
    9. Normal blood count (neutrophils > 1500/μL and platelet count> 130,000/mL), liver function (ALT, AST and alkaline phosphatase ≤2.5 x upper of normal limits [UNL], and total bilirubin <3.0 mg/ml in addition renal function (blood urea nitrogen and creatinine within the normal range, and, in particular, serum creatinine ≤ 1.5 x UNL).
    10. Written informed consent in accordance with the requirements of the local Ethical Committee.
    Pazienti con melanoma metastatico IIIc/IV M1a che incontrano i seguenti criteri di inclusione saranno eleggibili per lo studio.
    1. Età &gt; 18
    2. Melanoma cutaneo isto- e/o citologicamente confermato.
    3. Melanoma non oculare avanzato, stadio IIIC/IV M1 con presenza di lesioni multiple misurabili cutanee, sottocutanee biopsiabili e adatti per l'applicazione degli elettrodi;
    4. Numero di lesioni pari o superiore a sei con dimensioni minime delle lesioni di 0,5 cm.
    5. Performance status 0-2 (ECOG).
    6. Aspettativa di vita  3 mesi.
    7. Sedi di metastatizzazione misurabili e/o valutabili, secondo i criteri RECIST confermate da imaging. Tuttavia la valutazione delle lesioni potrà essere effettuata usando l’esame clinico con fotografia digitale e/o con l’ecografia.
    8. Un pregresso trattamento chemio- e/o immuno/bio-chemioterapico e/o una vaccinazione sono consentiti (comunque, è richiesto un periodo di wash-out di almeno 4 settimane).
    9. Normale esame emocromocitometrico (neutrofili &gt; 1500/μL e conta piastrinica &gt;130,000/μL), funzionalità epatica (livelli di ALT, AST e fosfatasi alcalina ≤ 2.5 x ai limiti superiori dei livelli normali [UNL]; e bilirubina totale &lt; 3.0 mg/ml; inoltre funzionalità renale (azotemia e creatininemia entro il range di normalità, e, in particolare, creatininemia ≤1.5 x UNL).
    10. Consenso informato scritto in accordo con le richieste del Comitato Etico Locale.
    E.4Principal exclusion criteria
    1. Previous cancers diagnosed within the last 2 years, with the exception of treated basal cell carcinomas or carcinomas in situ of the cervix treated properly.
    2. Recent major surgery (within 28 days before the start of study treatment).
    3. Previous treatment with bleomycin at maximum dosage, and different cancer therapies administered within 4 weeks prior to ECT.
    4. Pregnancy and lactation. Post-menopausal women should be with amenorrhea for at least 12 months.
    5. Serious diseases of the liver or lung.
    6. Short life expectancy (<3 months) in relation to the evolutionary picture of the disease.
    7. Evidence of bleeding diathesis or coagulopathy.
    8. Uncontrolled hypertension;
    9. Congestive heart failure (NYHA grade  2), previous myocardial infarction or cerebrovascular events within 6 months, pulmonary hypertension, unstable angina, cardiac arrhythmia not adequately controlled by medical treatment which cause decisive alteration in severe cardiac hemodynamics requiring specific treatment;
    10. Presence of epilepsy or history of significant neurological or psychiatric illness that would compromise the understanding and giving informed consent;
    11. Chronic renal failure
    12. Infection that requires intravenous antibiotic therapy and tuberculosis treatment upon entering the trial;
    13. Active peptic ulcer, unstable diabetes mellitus and other uncontrolled significant diseases, at the investigator discretion.
    14. A positive HIV test.
    15. Significant alterations of complete blood count (CBC) and / or of the of hepatic/renal function indices (mentioned above).
    Pazienti con melanoma metastatico che incontrano i seguenti criteri di esclusione non saranno eleggibili per lo studio:
    1. Precedenti tumori diagnosticati entro gli ultimi 2 anni, con l’eccezione di carcinomi basocellulari curati o carcinomi in situ della cervice adeguatamente trattati.
    2. Recenti interventi di chirurgia maggiore (entro 28 giorni prima dell’inizio del trattamento in studio).
    3. Precedente trattamento con bleomicina al dosaggio massimo, e differenti terapie antitumorali somministrate entro 4 settimane prima dell’ECT.
    4. Gravidanza ed allattamento. Le donne in post-menopausa devono essere in amenorrea per almeno 12 mesi.
    5. Malattie gravi del fegato o del polmone.
    6. Aspettativa di vita breve (&lt;3 mesi) in relazione al quadro evolutivo della malattia.
    7. Evidenza di diatesi emorragica o coagulopatia.
    8. Ipertensione arteriosa non controllata;
    9. Insufficienza cardiaca congestizia (NYHA grado  2), precedente infarto miocardico od eventi cerebrovascolari entro 6 mesi, ipertensione polmonare, angina instabile, aritmia cardiaca non adeguatamente controllata dal trattamento medico determinante alterazione dell’emodinamica cardiaca severa che richieda trattamento specifico;
    10. Presenza di epilessia o storia di significative malattie neurologiche o psichiatriche che comprometterebbero la comprensione ed il rilascio del consenso informato;
    11. Insufficienza renale cronica
    12. Infezione che richiede una terapia antibiotica per via endovenosa e tubercolosi in trattamento al momento dell’ingresso in trial;
    13. Ulcera peptica attiva, diabete mellito instabile ed altre malattie significative, non controllate a giudizio del ricercatore.
    14. Positività al test dell’HIV.
    15. Alterazioni significative dell’emocromo e/o degli indici di funzionalità epatica/renale (sopra menzionati)
    E.5 End points
    E.5.1Primary end point(s)
    1. Significant increase in the systemic anti-tumor immune response (evaluated as IFN gamma Elispost in response to autologous melanoma cells or HLA-compatible antigenic peptides and phenotypic profile leukocyte, including of immunosoppressorie subpopulations immunosoppressorie as Treg and MDSC) in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment;
    2. Increase of pathological tumor response and of the anti-tumor immune infiltrate T, possibly associated with a decrease of negative regulatory cells (Treg and MDSC) in ECT treated lesions, in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment.
    The statistical analysis will be carried out by comparing the immune response probability in the three trial arms; for such a task, the Pearson’s chi square test at the 5% significance level will be adopted.
    It is planned to enroll 21 patients per trial arm. With such a sample size, the study power is 80% under the assumption of a 10% response probability in the control arm and a 50% response probability in each experimental arm.
    1. Aumento significativo della risposta immunitaria anti-tumorale sistemica (valutata come IFN gamma Elispost in risposta a cellule di melanoma autologhe o HLA-compatibili peptidi antigenici e profilo fenotipico leucocitario, inclusivo di sottopopolazioni immunosoppressorie quali Treg ed MDSC) nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo;
    2. Aumento della risposta tumorale patologica e dell’infiltrato immunitario T anti-tumorale, eventualmente associato ad una diminuzione di cellule regolatorie negative (Treg ed MDSC) nelle lesioni trattate con ECT, nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo;
    La frequenza di risposte immunitarie nei tre bracci dello studio sarà confrontata mediante test Chi-quadrato di Pearson, al livello di significatività del 5%.
    È previsto il reclutamento di 21 pazienti per braccio. Tale numerosità garantisce una potenza dell’80% sotto l’assunto di una probabilità di risposta del 10% nel braccio di controllo e del 50% per ciascuno dei due bracci sperimentali.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Analysis of tumor response, toxicity and immunologic response will be performed respectively at day 1 (only in the arm B) and after 4, 8, and 15 weeks dall'ECT (day 31, 59, 91, and 119) in all three arms of treatment, and, subsequently, according to the standards of follow-up. The duration of response will be considered starting from the fifth week post-ECT and until the date of relapse / progression or last follow-up.
    Analisi della risposta tumorale, tossicità e risposta immunologica saranno eseguite rispettivamente a giorno 1 (solo nel braccio B) e dopo 4, 8, e 15 settimane dall’ECT (giorno 31, 59, 91, e 119) in tutti e tre i bracci di trattamento, e, successivamente, secondo gli standard di follow-up. La durata della risposta sarà considerata a partire dalla quinta settimana post-ECT e fino alla data della eventuale recidiva / progressione o all'ultimo follow-up.
    E.5.2Secondary end point(s)
    1. Improvement of clinical response (assessed as % regression and TTR or TTP) in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment;
    2. Achievement of clinical response in untreated lesions, as a sign of systemic acquired effecacy in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment, assessed clinically or pathologically;
    3. Reduction of frequency and / or activity of negative regulation immune cells to, as MDSC and Treg in the peripheral blood of patients enrolled in the arms of combination ECT IL2 and ECT LANS, compared to ECT as a single treatment
    1. Miglioramento della risposta clinica (valutata come % di regressione e TTR o TTP) nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo;
    2. Risposta clinica nelle lesioni non trattate, come segno di acquisita efficacia sistemica nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo, valutata clinicamente o patologicamente;
    3. Riduzione della frequenza e/o dell’attività di cellule immunitarie a regolazione negativa, come MDSC e Treg, nel sangue periferico dei pazienti arruolati nei bracci di combinazione ECT+IL2 e ECT+LANS, rispetto ad ECT come trattamento singolo
    E.5.2.1Timepoint(s) of evaluation of this end point
    The metabolic response in all patients will be assessed by performing the PET scan at baseline and 3 months after treatment in each of three treatment arms.
    La risposta metabolica sarà valutata in tutti i pazienti eseguendo la scansione PET al baseline e 3 mesi dopo il trattamento in ciascuno dei tre bracci di trattamento.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunological tumor response in pts treated with ECT ± immunomodulator drugs
    Valutare la risposta immunologica in pazienti trattati con ECT ± farmaci immunomodulatori
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    terapia standard (solo ECT)
    standard therapy (ECT)
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    "LVLS"
    "LVLS"
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 50
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 13
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state63
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After participation in the study the investigator will assess the best available therapeutic option at that time to offer to the patient, in relation to the clinical conditions, and to the stage of the disease.
    Al termine della partecipazione allo studio lo sperimentatore valuterà la migliore opzione terapeutica disponibile in quel momento da offrire al paziente, in relazione alle condizioni cliniche e allo stato della malattia.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-06-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-06-28
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2013-06-20
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:44:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA